[go: up one dir, main page]

WO1998040083A1 - Preparation medicinale contenant un gaz inerte lipophile - Google Patents

Preparation medicinale contenant un gaz inerte lipophile Download PDF

Info

Publication number
WO1998040083A1
WO1998040083A1 PCT/EP1998/001304 EP9801304W WO9840083A1 WO 1998040083 A1 WO1998040083 A1 WO 1998040083A1 EP 9801304 W EP9801304 W EP 9801304W WO 9840083 A1 WO9840083 A1 WO 9840083A1
Authority
WO
WIPO (PCT)
Prior art keywords
xenon
anaesthesia
emulsion
inert gas
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1998/001304
Other languages
English (en)
Inventor
Michael Georgieff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to SK1187-99A priority Critical patent/SK284249B6/sk
Priority to HK00107595.4A priority patent/HK1028335B/xx
Priority to AT98913672T priority patent/ATE207754T1/de
Priority to AU68286/98A priority patent/AU738946C/en
Priority to DE69802268T priority patent/DE69802268T2/de
Priority to EEP199900399A priority patent/EE03807B1/xx
Priority to IL13155798A priority patent/IL131557A0/xx
Priority to PL98335444A priority patent/PL189841B1/pl
Priority to BR9808227-2A priority patent/BR9808227A/pt
Priority to APAP/P/1999/001630A priority patent/AP1162A/en
Priority to SI9830049T priority patent/SI0966291T1/xx
Application filed by Individual filed Critical Individual
Priority to CA002283227A priority patent/CA2283227A1/fr
Priority to NZ337534A priority patent/NZ337534A/xx
Priority to HU0001510A priority patent/HU224985B1/hu
Priority to EP98913672A priority patent/EP0966291B1/fr
Priority to DK98913672T priority patent/DK0966291T3/da
Priority to KR10-1999-7008165A priority patent/KR100504287B1/ko
Priority to UA99105498A priority patent/UA64744C2/uk
Publication of WO1998040083A1 publication Critical patent/WO1998040083A1/fr
Priority to NO994091A priority patent/NO994091L/no
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/08—Bellows; Connecting tubes ; Water traps; Patient circuits
    • A61M16/0816—Joints or connectors
    • A61M16/0841—Joints or connectors for sampling
    • A61M16/085—Gas sampling
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00—Measuring parameters of the user
    • A61M2230/40—Respiratory characteristics
    • A61M2230/43—Composition of exhalation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00—Measuring parameters of the user
    • A61M2230/40—Respiratory characteristics
    • A61M2230/43—Composition of exhalation
    • A61M2230/437—Composition of exhalation the anaesthetic agent concentration

Definitions

  • a further object of the present invention is to provide a liquid preparation for inflammation therapy.
  • Another object of the present invention is the provision of an infusion agent for inducing or maintaining anaesthesia which overcomes all or some of the draw backs of the above described prior art.
  • Still another object of the invention relates to methods of treatment wherein a preparation will be parenterally administered to induce anaesthesia, sedation, analgesia and/or muscle relaxation.
  • a preparation will be parenterally administered to induce anaesthesia, sedation, analgesia and/or muscle relaxation.
  • the present invention contemplates to utilize gases as such or mixtures thereof, such as xenon and/or krypton.
  • Blood substitutes especially perfluorocarbon emulsions (e.g. Perflubron) , can be regarded as examples of such liquids.
  • perfluorocarbon emulsions e.g. Perflubron
  • Perfluorocarbons can be administered intrapulmo- narily, inter alia, so when they are loaded with xenon they can also be used on the one hand to treat acute lung damage, but on the other hand also to induce anaesthesia, sedation and/or analgesia on the basis of the pharmacological action of xenon.
  • the intrapulmo- nary administration of perfluorocarbon together with xenon for partial liquid ventilation and additionally for anaesthesia or else alleviation of pain is a novel approach to the treatment of severe respiratory crises. It reopens collapsed, atelectatic areas of the lung which cannot be reached by conventional therapy, thereby preparing these areas of the lung for renewed gas exchange.
  • monobrominated perfluorocarbons for example 1-bromoheptadecafluorooctane (CaFi ⁇ Br) , 1- bromopentadecafluoroheptane (C 7 F 15 Br) and 1-bromotri- decafluorohexane .
  • Other compounds can also be used, including perfluoroalkylated ethers or poly- ethers, e.g.
  • the volume of the gas to be included in the liquid preparation of the present invention may be measured by simple methods known to the skilled person, such as gravimetric measurements or other analytical means, or control measurements with for instance radioactive xenon (i.e. Xenon 133) as described by Gerald L. Pollack (see above) .
  • the invention also provides (fatty) emulsions containing the lipophilic inert gas dissolved or dispersed in the lipid phase.
  • xenon can be added to an (fatty) emulsion in appreciable amounts.
  • xenon can be dissolved or dispersed in concentrations of 0.2 to 10 ml or more per ml of emulsion (concentrations relate to standard conditions, i.e. 20°C and normal pressure).
  • concentrations relate to standard conditions, i.e. 20°C and normal pressure.
  • the xenon concentration depends on a large number of factors, especially the concentration of the fat or lipophilic substance.
  • the preparations according to the invention will be "loaded” with xenon up to the saturation limit.
  • very small concentrations to be present, provided, for example, that a pharmacological activity can still be observed on intravenous administration.
  • solubility of the inert gas in the emulsions can be increased by using so-called solubility promotors such as smaller lipophilic compounds which may or may not have a pharmaceutical effect (molecular weight of about 30 to about 1000; n-octanol/water partition coefficient preferably greater than 500) . It has been found that aromatic compounds such as 2,6- dialkylphenols (e.g. 2 , 6-diisopropylphenol) significantly improve the loading capacity of emulsions for inert gases.
  • solubility promotors such as smaller lipophilic compounds which may or may not have a pharmaceutical effect (molecular weight of about 30 to about 1000; n-octanol/water partition coefficient preferably greater than 500) .
  • aromatic compounds such as 2,6- dialkylphenols (e.g. 2 , 6-diisopropylphenol) significantly improve the loading capacity of emulsions for inert gases.
  • contrast media containing a gas especially for ultrasound studies or nuclear magnetic resonance spectrometry .
  • An essential feature of such contrast media is that a separate phase is formed which is made up of very small gas bubbles (or even gas- filled balloons) (cf. inter alia WO-A-96/39197 , US-A- 5 088 499, US-A-5 334 381, WO-A-96/41647 ) .
  • gases including especially air, nitrogen, carbon dioxide, oxygen and also inert gases in general (i.e. helium, argon, xenon and neon).
  • EP-B-0 357 163 discloses in definite terms that xenon- containing media in particular can be used as X-ray contrast media.
  • the injectable solution must contain gas bubbles.
  • WO-A-95/27438 discloses the use of xenon in a method of imaging of a noble gas by nuclear magnetic resonance.
  • xenon has an analgesic or anaesthetic action when used as a contrast medium or for spectrometry. In fact, such an action would also be undesirable.
  • the gas concentration in contrast media is also so small that the limiting concentration for a pharmacological action is not reached. Therefore, contrast media as such or formulations to be used in spectrometry are not claimed in the present patent application.
  • the lipid phase of the preparation which takes up the gas, i.e. which can dissolve and/or disperse the gas, is formed mainly of so-called fats, said fats being essentially esters of long-chain and medium-chain fatty acids.
  • Such fatty acids saturated or unsatu- rated, contain 8 to 20 carbon atoms.
  • omega-3 or omega-6 fatty acids which can contain up to 30 carbon atoms.
  • Suitable esterified fatty acids are especially plant oils, e.g. cottonseed oil, soya bean oil and thistle oil, fish oil and the like.
  • the major constituent of these naturally occurring oils are fatty acid triglycerides.
  • Preparations in the form of so-called oil-in-water emulsions are of particular importance, the proportion of fat in the emulsion conventionally being 5 to 30% by weight, preferably 10 to 20% by weight.
  • an emulsifier is present together with the fat, proven emulsifiers being soya phosphatides, gelatin or egg phosphatide.
  • Such emulsions can be prepared by emulsifying the water-immiscible oil with water in the presence of the emulsifier, which is normally a surface-active agent.
  • polar solvents can also be present with the water, examples being ethanol and glycerol (propylene glycol, hexylene glycol, polyethylene glycol, glycol monoethers, a water-miscible ester, etc.).
  • the inert gas can already have been incorporated into the lipid phase in a previous process step. In the simplest case, however, the preprepared emulsion is loaded with the xenon. This can take place at various temperatures, for example at temperatures from 1°C to room temperature. It is occasionally useful here to apply a pressure, for example of up to 8 atmospheres or more, to the vessel containing the emulsion.
  • fatty emulsions such as those employed in intravenous feeding.
  • These fatty emulsions consist essentially of a suitable fatty base (soya bean oil or sunflower seed oil) and a well-tolerated emulsifier (phosphatides) .
  • Fatty emulsions in general use are Intralipid ® ,
  • the fatty emulsions generally also contain additives which make the osmolarity of the aqueous phase, surrounding the fatty phase present in the form- of liposomes, isotonic with the blood. Glycerol and/or xylitol can be used for this purpose. Furthermore, it is frequently useful to add an antioxidant to the fatty emulsion in order to prevent oxidation of the unsatu- rated fatty acids. Vitamin E (DL-tocopherol) , in particular, is suitable for this purpose.
  • US-A-5 334 381 illustrates in detail how liposomes can be loaded with gas.
  • a device is filled with the liposomes, i.e. with an oil- in-water emulsion, and the device is then pressurized with the gas inside.
  • the temperature can be reduced to as low as 1°C in this process.
  • the gas gradually dissolves under pressure and passes into the liposomes.
  • the lipids which form the liposomes can be of natural or synthetic origin. Examples of such materials are cholesterol, phosphatidylcholine, phos- phatidylethanolamine, phosphatidylserine, phosphatidyl- glycerol, phosphatidylinositol, sphingomyelin, glyco- sphingolipids, glucolipids, glycolipids, etc.
  • the surface of the liposomes can moreover be modified by a polymer, for example by polyethylene glycol.
  • the preparations according to the invention thus have a large number of advantages .
  • a virtually immediate anaesthetic effect took place which, in contrast to all known injectable anaesthetics, could easily be controlled.
  • the agent according to the invention has not only an anaesthetic action but also a simultaneous analgesic action and, on waking, a euphoretic action.
  • the elimination from the body depends exclusively on the respiration.
  • an intravenous anaesthetic the xenon concentration can easily be measured in the exhaled air. The control of anaesthesia which can be achieved in this way was not possible hitherto with conventional intravenous anaesthetics.
  • the invention thus provides medicinal liquid preparations containing a lipophilic inert gas in a pharmacologically effective concentration with the proviso that preparations used as contrast media or for spectrometry are excluded.
  • Pharmacologically effective is understood here as meaning anaesthetic (including subanaesthetic) , analgesic, muscle relaxing, sedative and/or anti-inflammatory.
  • the pharmacological effectiveness of the present invention may relate to the systemic action on the central nervous system.
  • the xenon load in the medicinal preparation may be about 0.2 to 0.3 ml of xenon per ml of emulsion.
  • An anti-inflammatory action may be already observed at 0.1 ml/ml emulsion. It was observed that, with continuous infusion over 30 sec, 20 ml of an emulsion containing 0.3 ml of Xe per ml of emulsion produce a subanaesthetic condition in a patient weighing about 85 kg.
  • the above given concentration limits may be operative for preparations comprising 10 to 40 % (weight/volume) lipid or fluorocarbon emulsions.
  • the present invention also contemplates emulsions comprising more than 40 % w/v and up to 125 % w/v of for instance hydrocarbon compounds; e.g. fluorinated and/or chlorinated derivatives thereof. With such emulsions the loading capacity of the liquid preparation may be well above the above given limits.
  • the emulsions as such impact the efficacy of the xenon in the liquid preparation. Thus, for certain indications the required xenon concentration may be drastically lower.
  • the preparation according to the invention can thus be combined with any known inhalation anaesthetic, i.e. an i.v. administration is accompanied by inhalation anaesthesia.
  • any known inhalation anaesthetic i.e. an i.v. administration is accompanied by inhalation anaesthesia.
  • the concentration or amount of inhalation anaesthetic used can be reduced.
  • Another pharmacologically active agent in the preparation in addition to the inert gas.
  • This can be an intravenous sedative or anaesthetic, for example.
  • this agent is water-soluble or fat-soluble, it is then present in the aqueous phase or the lipid phase together with the xenon. 2
  • 6-Diisopropylphenol which is an effective anaesthetic (for example 1.5 - 20 mg/ml) , is found to be particularly suitable for this purpose.
  • fatty emulsion according to the invention can contain 2.5 - 20 mg of 2 , 6-diisopropylphenol, i.e. for example 2.5, 5.0, 7.5, 10, 15 or 20 mg, in addition to the xenon.
  • the substance with an anaesthetic, analgesic or sedative action which is present together with the xenon can be another anaesthetic, an analgesic, a muscle relaxant or a sedative.
  • suitable anaesthetics are barbiturates (barbital, phenobarbital, pentobarbital , secobarbital , hexobarbital and thiopental, inter alia) in general, and opioids.
  • Known analgesics are, inter alia, compounds of the morphine type, e.g.
  • anthranilic acid derivatives flufenamic acid, mefena ic acid
  • acrylic acid derivatives diclofenac, tolmetin, zomepirac
  • arylpropionic acid derivatives ibuprofen, naproxen, phenoprofen, ketoprofen
  • indoleacetic or indenacetic acid derivatives indometacin, sulindac
  • a preparation according to the invention can consequently serve several purposes: a) intravenous induction of anaesthesia (optionally with 2 , 6-diisopropylphenol or etomidate as a supporting component) ; b) supplementary intravenous administration in parallel with inhalation anaesthesia with xenon or another gas (e.g. laughing gas or desflurane) , it being possible considerably to reduce the amount of gas to be used overall; c) maintenance of anaesthesia over a prolonged period, the inert gas-containing preparation optionally being administered only as a supplement together with
  • anaesthesia as the field of use.
  • anaesthesia here includes both the induction and the maintenance of anaesthesia.
  • the preparations according to the invention also have a pain eliminating action, which can become significant in conjunction with anaesthesia.
  • the elimination of pain for example acute and chronic pain therapy, also comes to the fore, a degree of additional subanaesthetic or sedative action often being desirable.
  • Intravenous administration in a subanaesthetic dose over a long period of time (1 h to several days) effects an increased pain inhibiting action.
  • One particular field of use of a preparation according to the invention as an anaesthetic is emergency medicine.
  • the invention can thus be understood as a liquid or gel-like preparation containing the inert gas in dissolved or dispersed form.
  • the liquid or gel-like preparation according to the invention is characterized in that it contains the gas with the pharmacological action dissolved in a finely divided, separate phase.
  • this separate phase is the disperse phase of a dispersion or emulsion.
  • the separate phase containing the gas can also be the continuous phase.
  • the preparations according to the invention are generally composed in such a way that the disperse phase as such has the property of dissolving the gas.
  • a series of perfluorocarbon emulsions were prepared or purchased and loaded with xenon. The activity of the preparations was verified on an animal model (rabbit) . All the emulsions were used in the same way as the Intralipid preparations described above, i.e. the experimental animal was quickly anaesthetized by an injection in the ear (about 1 ml) .
  • Each of the emulsions was placed in a beaker and loaded by having the xenon gas passed through it.
  • perfluorocarbon compounds perfluorohexyloctane (1) , perfluorodecalin (2) , per- flubron (C 8 F 17 ) (3) .
  • said compound (I-IV) is liquid or gaseous at room temperature (20°C) and has an oil/water partition coefficient (in n-octanol; 20°C) of about 20.

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne une préparation contenant un gaz lipophile à action pharmaceutique sous forme dissoute ou dispersée. Cette préparation est particulièrement conçue à des fins anesthésiques.
PCT/EP1998/001304 1997-03-10 1998-03-06 Preparation medicinale contenant un gaz inerte lipophile Ceased WO1998040083A1 (fr)

Priority Applications (19)

Application Number Priority Date Filing Date Title
SI9830049T SI0966291T1 (en) 1997-03-10 1998-03-06 Medicinal preparation containing a lipophilic inert gas
AT98913672T ATE207754T1 (de) 1997-03-10 1998-03-06 Medizinische präparation,die ein lipophiles edelgas enthält
AU68286/98A AU738946C (en) 1997-03-10 1998-03-06 Medicinal preparation containing a lipophilic inert gas
DE69802268T DE69802268T2 (de) 1997-03-10 1998-03-06 Medizinische präparation,die ein lipophiles edelgas enthält
EEP199900399A EE03807B1 (et) 1997-03-10 1998-03-06 Lipofiilset inertgaasi sisaldav meditsiiniline preparaat
IL13155798A IL131557A0 (en) 1997-03-10 1998-03-06 Medical preparation containing a lipophilic inert gas
CA002283227A CA2283227A1 (fr) 1997-03-10 1998-03-06 Preparation medicinale contenant un gaz inerte lipophile
HK00107595.4A HK1028335B (en) 1997-03-10 1998-03-06 Medicinal preparation containing a lipophilic inert gas
APAP/P/1999/001630A AP1162A (en) 1997-03-10 1998-03-06 Medical preparation containing a lipophilic inert gas.
SK1187-99A SK284249B6 (sk) 1997-03-10 1998-03-06 Medicinálny prípravok obsahujúci lipofilný inertný plyn
BR9808227-2A BR9808227A (pt) 1997-03-10 1998-03-06 Preparação medicinal contendo gás inerte lipofìlico
PL98335444A PL189841B1 (pl) 1997-03-10 1998-03-06 Ciekły preparat w postaci emulsji do zastosowań medycznych
NZ337534A NZ337534A (en) 1997-03-10 1998-03-06 Liquid emulsion containing a lipophilic inert gas such as xenon useful as an anaesthetic, analgesic or muscle relaxant
HU0001510A HU224985B1 (en) 1997-03-10 1998-03-06 Medicinal preparation containing a lipophilic inert gas
EP98913672A EP0966291B1 (fr) 1997-03-10 1998-03-06 Preparation medicinale contenant un gaz inerte lipophile
DK98913672T DK0966291T3 (da) 1997-03-10 1998-03-06 Medicinsk præparat, som indeholder en lipofil ædelgas
KR10-1999-7008165A KR100504287B1 (ko) 1997-03-10 1998-03-06 친유성 불활성 가스를 함유하는 약물제제
UA99105498A UA64744C2 (en) 1997-03-10 1998-06-03 Medicinal preparation containing lipophilic inert gas
NO994091A NO994091L (no) 1997-03-10 1999-08-24 Medisinsk preparat inneholdende en lipofilisk inertgass

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19709704A DE19709704C2 (de) 1997-03-10 1997-03-10 Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
DE19709704.9 1997-03-10
EP97113757.5 1997-08-08

Publications (1)

Publication Number Publication Date
WO1998040083A1 true WO1998040083A1 (fr) 1998-09-17

Family

ID=7822782

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP1998/001305 Ceased WO1998040084A1 (fr) 1997-03-10 1998-03-06 Dispositif pour anesthesie, analgesie et/ou sedation controlees
PCT/EP1998/001304 Ceased WO1998040083A1 (fr) 1997-03-10 1998-03-06 Preparation medicinale contenant un gaz inerte lipophile

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/001305 Ceased WO1998040084A1 (fr) 1997-03-10 1998-03-06 Dispositif pour anesthesie, analgesie et/ou sedation controlees

Country Status (32)

Country Link
US (3) US6197323B1 (fr)
EP (3) EP0864329B1 (fr)
JP (1) JPH10251142A (fr)
KR (2) KR100504287B1 (fr)
CN (1) CN1104901C (fr)
AP (1) AP1162A (fr)
AT (3) ATE198047T1 (fr)
AU (1) AU738946C (fr)
BG (1) BG64583B1 (fr)
BR (1) BR9808227A (fr)
CA (1) CA2283227A1 (fr)
CZ (1) CZ292767B6 (fr)
DE (4) DE19709704C2 (fr)
DK (2) DK0864329T3 (fr)
EE (1) EE03807B1 (fr)
ES (2) ES2152608T3 (fr)
GR (1) GR3035553T3 (fr)
HU (1) HU224985B1 (fr)
ID (1) ID23151A (fr)
IL (1) IL131557A (fr)
NO (1) NO994091L (fr)
NZ (1) NZ337534A (fr)
OA (1) OA11156A (fr)
PL (1) PL189841B1 (fr)
PT (2) PT864329E (fr)
RU (1) RU2204397C2 (fr)
SI (1) SI0966291T1 (fr)
SK (1) SK284249B6 (fr)
TR (1) TR199902205T2 (fr)
TW (2) TW396040B (fr)
WO (2) WO1998040084A1 (fr)
ZA (2) ZA981958B (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU757361B2 (en) * 1999-03-11 2003-02-20 Imperial Innovations Limited Use of xenon for treating neurointoxications
US6562855B1 (en) 1999-06-11 2003-05-13 Nicholas Peter Franks Anaesthetic formulation comprising an NMDA-antagoinst and an alpha-2 adrenergic agonist
US6653354B2 (en) 1999-07-29 2003-11-25 Protexeon Limited NMDA antagonist comprising xenon
WO2003105872A1 (fr) * 2002-06-12 2003-12-24 Messer Griesheim Gmbh Spasmolytique a base de xenon
EP1570852A3 (fr) * 2000-09-14 2005-11-23 Air Liquide Deutschland GmbH Utilisation thérapeutique du xénon
US7235264B2 (en) 2002-06-12 2007-06-26 Air Liquide Deutschland Gmbh Cerebral protection with a gas comprising xenon
KR100881241B1 (ko) * 2000-09-15 2009-02-05 백스터 인터내셔널 인코포레이티드 흡입 마취제용 용기
US9278048B2 (en) 2009-05-06 2016-03-08 Baxter International, Inc. Pharmaceutical product and method of use

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19709704C2 (de) * 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
WO1999062403A1 (fr) * 1998-06-03 1999-12-09 Scott Laboratories, Inc. Appareil et technique visant a soulager la douleur et a diminuer l'anxiete associees a des interventions medicales ou chirurgicales chez un patient conscient
DE19833014A1 (de) * 1998-07-23 2000-01-27 Messer Griesheim Gmbh Edelgashaltige Injektionsanästhesiemittel
WO2000010531A1 (fr) 1998-08-19 2000-03-02 Rtp Pharma Inc. Dispersions aqueuses injectables de propofol
DE19851604A1 (de) * 1998-11-09 2000-05-11 Messer Griesheim Gmbh Injektionsanästhesiemittel mit hydrophiler Phase
DE19851605A1 (de) * 1998-11-09 2000-05-11 Messer Griesheim Gmbh Mikropartikel enthaltendes Injektionsanästhesiemittel
DE19852472A1 (de) * 1998-11-13 2000-05-25 Messer Griesheim Gmbh Analyse von mit Gasen beladenen Flüssigkeiten
AU5985900A (en) * 1999-07-19 2001-02-05 Michael Georgieff Novel spinal and epidural anaesthetic
GB9917822D0 (en) * 1999-07-29 1999-09-29 Imperial College Nmda antagonist
AU777817B2 (en) 1999-11-08 2004-11-04 University Of Florida Research Foundation, Inc. Marker detection method and apparatus to monitor drug compliance
US20050037374A1 (en) * 1999-11-08 2005-02-17 Melker Richard J. Combined nanotechnology and sensor technologies for simultaneous diagnosis and treatment
US20050233459A1 (en) * 2003-11-26 2005-10-20 Melker Richard J Marker detection method and apparatus to monitor drug compliance
US20020177232A1 (en) * 2001-05-23 2002-11-28 Melker Richard J. Method and apparatus for detecting illicit substances
US6623765B1 (en) * 2000-08-01 2003-09-23 University Of Florida, Research Foundation, Incorporated Microemulsion and micelle systems for solubilizing drugs
FR2812545B1 (fr) * 2000-08-03 2003-03-28 Air Liquide Sante Int Aerosol medicamenteux inhalable dans le traitement ou la prevention de la douceur
US7104963B2 (en) * 2002-01-22 2006-09-12 University Of Florida Research Foundation, Inc. Method and apparatus for monitoring intravenous (IV) drug concentration using exhaled breath
US6981947B2 (en) 2002-01-22 2006-01-03 University Of Florida Research Foundation, Inc. Method and apparatus for monitoring respiratory gases during anesthesia
WO2002045721A1 (fr) * 2000-12-04 2002-06-13 Uws Ventures Limited Complexes a base de gaz noble
US7052854B2 (en) 2001-05-23 2006-05-30 University Of Florida Research Foundation, Inc. Application of nanotechnology and sensor technologies for ex-vivo diagnostics
WO2002095398A1 (fr) 2001-05-24 2002-11-28 University Of Florida Procede et appareil de detection de l'exposition a un environnement de fumee
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
AU2002350108B2 (en) * 2001-11-01 2008-09-11 Scott Laboratories, Inc. User interface for sedation and analgesia delivery systems and methods
US20070167853A1 (en) * 2002-01-22 2007-07-19 Melker Richard J System and method for monitoring health using exhaled breath
DE10205056A1 (de) * 2002-02-07 2003-08-14 Hartwin Hobler Gesteuerte Mischung von Fluids für medizinische und biologische Anwendungen
GB0209998D0 (en) † 2002-05-01 2002-06-12 Protexeon Ltd Use
CN1668358A (zh) * 2002-05-16 2005-09-14 斯科特实验室公司 用于镇静和止疼的成套医疗供给组件
US20040022842A1 (en) * 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
US20050255169A1 (en) * 2002-07-05 2005-11-17 Messer Griesheim Adjuvant containing xenon
GB0218153D0 (en) * 2002-08-05 2002-09-11 Ic Innovations Ltd An analgesic agent for newborn or retal subjects
US8028694B2 (en) * 2002-10-03 2011-10-04 Scott Laboratories, Inc. Systems and methods for providing trend analysis in a sedation and analgesia system
US20060160134A1 (en) * 2002-10-21 2006-07-20 Melker Richard J Novel application of biosensors for diagnosis and treatment of disease
AU2003288214A1 (en) * 2002-12-06 2004-06-30 Michael Georgieff Nasal pharmaceutical preparation containing an active lipophilic liquid or gaseous ingredient
WO2004066839A1 (fr) * 2003-01-23 2004-08-12 University Of Florida Research Foundation, Inc. Procede et dispositif de controle de la concentration intraveineuse (iv) en medicaments au moyen de l'air expire
RU2228739C1 (ru) * 2003-06-05 2004-05-20 Закрытое акционерное общество "АТОМ-МЕД ЦЕНТР" Препарат для адаптогенной терапии (варианты) и способ его изготовления
AU2004280118B2 (en) * 2003-10-10 2009-01-15 Imperial Innovations Limited Use of xenon with hypothermia for treating neonatal asphyxia
CA2542412A1 (fr) * 2003-10-21 2005-05-06 Aga Ab Emploi du xenon pour contrer la mort programmee des cellules
US20050191757A1 (en) * 2004-01-20 2005-09-01 Melker Richard J. Method and apparatus for detecting humans and human remains
US7622153B2 (en) * 2004-08-13 2009-11-24 M&G Usa Corporation Method of making vapour deposited oxygen-scavenging particles
US20060062734A1 (en) * 2004-09-20 2006-03-23 Melker Richard J Methods and systems for preventing diversion of prescription drugs
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
US20060257883A1 (en) * 2005-05-10 2006-11-16 Bjoraker David G Detection and measurement of hematological parameters characterizing cellular blood components
US7914460B2 (en) 2006-08-15 2011-03-29 University Of Florida Research Foundation, Inc. Condensate glucose analyzer
AU2009206391A1 (en) 2008-01-22 2009-07-30 Board Of Regents, The University Of Texas System Volatile anesthetic compositions and methods of use
AU2014277860A1 (en) * 2008-01-22 2015-01-22 Board Of Regents, The University Of Texas System Volatile anesthetic compositions and methods of use
US20110168177A1 (en) * 2008-09-17 2011-07-14 The Brigham And Women's Hospital, Inc. Anesthesia Simulator and Controller for Closed-Loop Anesthesia
CA3031836A1 (fr) 2009-05-05 2010-11-11 Board Of Regents, The University Of Texas System Formulations d'anesthesiques volatils pour reduire l'inflammation
BR112012023421B1 (pt) 2010-03-17 2021-09-14 Novaliq Gmbh Composição farmacêutica para tratamento de aumento de pressão intraocular
CN101928636B (zh) * 2010-09-08 2012-11-14 营口艾特科技有限公司 含氙气的油脂类液体及其制备方法
CN101940538B (zh) * 2010-09-08 2012-07-04 营口艾特科技有限公司 含氙气的化妆品及其制备方法
CN101961051A (zh) * 2010-09-08 2011-02-02 营口艾特科技有限公司 含氙气的液体及其制备方法
EP2444063A1 (fr) 2010-10-20 2012-04-25 Novaliq GmbH Compositions pharmaceutiques liquides pour l'administration de principes actifs
EP2462921A1 (fr) 2010-11-11 2012-06-13 Novaliq GmbH Compositions pharmaceutiques liquides pour le traitement d'une maladie de la chambre postérieure de l'oeil
JP6073244B2 (ja) * 2011-01-04 2017-02-01 ノバリック ゲーエムベーハー 部分フッ素化アルカンを含むｏ／ｗエマルション
WO2012160179A2 (fr) 2011-05-25 2012-11-29 Novaliq Gmbh Composition pharmaceutique a base d'alcanes semifluoré
RU2475249C1 (ru) * 2011-10-05 2013-02-20 Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии Сибирского отделения РАМН Средство для наружной терапии хронических рецидивирующих воспалительных заболеваний кожи
WO2013110621A1 (fr) 2012-01-23 2013-08-01 Novaliq Gmbh Compositions de protéine stabilisées à base d'alcanes semi-fluorés
DE102012203897B4 (de) 2012-03-13 2014-11-27 Kist Europe Forschungsgesellschaft Mbh Vorrichtung zur Durchführung einer Anästhesie oder Analgosedierung und Verfahren zum Betreiben einer Vorrichtung zur Durchführung einer Anästhesie oder Analgosedierung
CN103565745A (zh) 2012-08-10 2014-02-12 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法
KR102158400B1 (ko) 2012-09-12 2020-09-22 노바리크 게엠베하 부분불소화 알칸의 혼합물을 포함하는 조성물
PL2895144T3 (pl) 2012-09-12 2017-07-31 Novaliq Gmbh Kompozycje semifluorowanych alkanów
JP6625966B2 (ja) 2013-03-15 2019-12-25 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 希ガスが豊富な液体ならびにその調製及び使用の方法
KR101545706B1 (ko) * 2013-05-10 2015-08-26 주식회사 아미팜 포스파티딜콜린을 포함하는 지방 분해용 조성물 및 이의 제조방법
KR102272568B1 (ko) 2013-07-23 2021-07-05 노바리크 게엠베하 안정화 항체 조성물
US20150328073A1 (en) * 2014-05-19 2015-11-19 Joseph Gerard Archer Hyperbaric Social Establishment or Residence
US10499838B2 (en) * 2015-04-24 2019-12-10 Drexel University Non-invasive brain water monitoring device for cerebral edema and cerebral autoregulation monitoring system and method
EP3722274B1 (fr) 2015-09-30 2023-06-07 Novaliq GmbH 2-perfluorobutyl pentane pour administration ophtalmique
CN111743882A (zh) 2015-09-30 2020-10-09 诺瓦利克有限责任公司 半氟化化合物和其组合物
PL3442480T3 (pl) 2016-06-23 2020-04-30 Novaliq Gmbh Sposób podawania miejscowego
JP7012075B2 (ja) 2016-09-22 2022-01-27 ノバリック ゲーエムベーハー 眼瞼炎の治療に使用するための医薬組成物
EP3515467B1 (fr) 2016-09-23 2023-11-29 Novaliq GmbH Composition ophtalmique comprenant ciclosporine
PL3612228T3 (pl) 2017-04-21 2024-04-08 Dermaliq Therapeutics, Inc. Kompozycje jodu
EP3621601A1 (fr) 2017-05-12 2020-03-18 Novaliq GmbH Compositions pharmaceutiques comprenant des alcanes semifluorés pour le traitement d'états liés aux lentilles de contact
SG11202002640YA (en) 2017-09-27 2020-04-29 Novaliq Gmbh Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
CA3076567A1 (fr) 2017-10-04 2019-04-11 Novaliq Gmbh Compositions ophtalmiques
EP3758676A1 (fr) 2018-03-02 2021-01-06 Novaliq GmbH Compositions pharmaceutiques contenant du nébivolol
CN112153970A (zh) 2018-04-27 2020-12-29 诺瓦利克有限责任公司 用于治疗青光眼的包含他氟前列素的眼用组合物
CA3112031A1 (fr) 2018-10-12 2020-04-16 Novaliq Gmbh Composition ophtalmique pour le traitement d'une maladie oculaire seche
JP2022512230A (ja) * 2018-12-14 2022-02-02 ペア セラピューティクス インコーポレイテッド ブプレノルフィン含有製品の誘導を最適化するためのデジタル治療構成要素
EP3923907B1 (fr) 2019-02-13 2024-09-25 Novaliq GmbH Compositions et procédés pour le traitement de la néovascularisation oculaire
EP3839959A1 (fr) * 2019-12-19 2021-06-23 Koninklijke Philips N.V. Commande de libération transdermique de sédatif dans l'imagerie autonome

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1667926A1 (de) * 1967-01-09 1971-11-04 Union Carbide Corp Verfahren zur Herstellung radioaktive Gase enthaltender Salzloesungen
WO1985000011A1 (fr) * 1983-06-17 1985-01-03 Univ Miami Micro-gouttelettes de medicaments insolubles dans l'eau
DE3940389A1 (de) * 1989-12-06 1991-06-13 Abolghassem Prof Dr M Pakdaman Therapeutisches mittel
DE4100782A1 (de) * 1991-01-12 1992-07-16 Patentverwertung Dr J Haensler Waessrige ozonpraeparate, verfahren zu ihrer herstellung und ihre verwendung
EP0523315A1 (fr) * 1991-07-16 1993-01-20 Praxair Technology, Inc. Mélange de xénon, oxygène et hélium pour anesthésie
WO1995027438A1 (fr) * 1994-04-08 1995-10-19 The Research Foundation Of State University Of New York Procede d'imagerie par resonance magnetique faisant intervenir des gaz rares hyperpolarises

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1472793A (en) * 1974-03-28 1977-05-04 Ici Ltd Pharmaceutical compositions
GR64915B (en) * 1978-09-14 1980-06-09 Janssen Pharmaceutica Nv Improved etomidate-containing compositions
US4725442A (en) * 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US5140981A (en) 1986-11-24 1992-08-25 Picker International, Inc. End-tidal gas detection
SE8700977D0 (sv) * 1987-03-09 1987-03-09 Olof Werner Enhet som i olika grad separerar gasinnehallet i drivkrets och mottagarkrets, men som enda tillater gasgenomslepp i bada riktningarna (oppen separation)
US4781698A (en) * 1987-04-09 1988-11-01 Parren Mark L Selectable drop size infusion metering device
DE3712598A1 (de) * 1987-04-14 1988-10-27 Siemens Ag Inhalations-anaesthesiegeraet
DE3828905A1 (de) * 1988-08-23 1990-03-15 Schering Ag Mittel bestehend aus cavitate oder clathrate bildenden wirt/gast-komplexen als kontrastmittel
US5088499A (en) 1989-12-22 1992-02-18 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5334381A (en) * 1989-12-22 1994-08-02 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5585112A (en) * 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5320093A (en) 1990-12-21 1994-06-14 Brigham And Women's Hospital Rapid anesthesia emergence system using closed-loop PCO2 control
DE4132677C2 (de) * 1991-10-01 1995-08-24 Braun Melsungen Ag Flüchtige Inhalationsnarkotika enthaltende Liposomen, ihre Herstellung und Verwendung
DE4411533C1 (de) * 1994-04-02 1995-04-06 Draegerwerk Ag Anästhesiegerät
DE4432378A1 (de) * 1994-09-12 1996-03-14 Bayer Ag Injizierbare liposomale Arzneizubereitungen
US5997898A (en) 1995-06-06 1999-12-07 Imarx Pharmaceutical Corp. Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery
US5780010A (en) * 1995-06-08 1998-07-14 Barnes-Jewish Hospital Method of MRI using avidin-biotin conjugated emulsions as a site specific binding system
US5807321A (en) * 1995-11-28 1998-09-15 Merit Medical System for electronically monitoring the delivery of contrast media
SE9601348D0 (sv) * 1996-04-10 1996-04-10 Pharmacia Ab Improved containers for parenteral fluids
SE9601719D0 (sv) * 1996-05-06 1996-05-06 Siemens Elema Ab Doserare för tillförsel av tillsatsgas eller vätska till andningsgas vid anestesiapparat eller ventilator
DE19709704C2 (de) * 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1667926A1 (de) * 1967-01-09 1971-11-04 Union Carbide Corp Verfahren zur Herstellung radioaktive Gase enthaltender Salzloesungen
WO1985000011A1 (fr) * 1983-06-17 1985-01-03 Univ Miami Micro-gouttelettes de medicaments insolubles dans l'eau
DE3940389A1 (de) * 1989-12-06 1991-06-13 Abolghassem Prof Dr M Pakdaman Therapeutisches mittel
DE4100782A1 (de) * 1991-01-12 1992-07-16 Patentverwertung Dr J Haensler Waessrige ozonpraeparate, verfahren zu ihrer herstellung und ihre verwendung
EP0523315A1 (fr) * 1991-07-16 1993-01-20 Praxair Technology, Inc. Mélange de xénon, oxygène et hélium pour anesthésie
WO1995027438A1 (fr) * 1994-04-08 1995-10-19 The Research Foundation Of State University Of New York Procede d'imagerie par resonance magnetique faisant intervenir des gaz rares hyperpolarises

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU757361B2 (en) * 1999-03-11 2003-02-20 Imperial Innovations Limited Use of xenon for treating neurointoxications
US6562855B1 (en) 1999-06-11 2003-05-13 Nicholas Peter Franks Anaesthetic formulation comprising an NMDA-antagoinst and an alpha-2 adrenergic agonist
AU778671B2 (en) * 1999-06-11 2004-12-16 Protexeon Limited Anaesthetic formulation comprising an NMDA-antagonist and an alpha-2 adrenergic agonist
US6653354B2 (en) 1999-07-29 2003-11-25 Protexeon Limited NMDA antagonist comprising xenon
EP1570852A3 (fr) * 2000-09-14 2005-11-23 Air Liquide Deutschland GmbH Utilisation thérapeutique du xénon
KR100881241B1 (ko) * 2000-09-15 2009-02-05 백스터 인터내셔널 인코포레이티드 흡입 마취제용 용기
KR100901049B1 (ko) * 2000-09-15 2009-06-04 백스터 인터내셔널 인코포레이티드 흡입 마취제용 용기
WO2003105872A1 (fr) * 2002-06-12 2003-12-24 Messer Griesheim Gmbh Spasmolytique a base de xenon
US7235264B2 (en) 2002-06-12 2007-06-26 Air Liquide Deutschland Gmbh Cerebral protection with a gas comprising xenon
US9278048B2 (en) 2009-05-06 2016-03-08 Baxter International, Inc. Pharmaceutical product and method of use

Also Published As

Publication number Publication date
ATE198047T1 (de) 2000-12-15
ATE207754T1 (de) 2001-11-15
TWI241914B (en) 2005-10-21
EP0864329A1 (fr) 1998-09-16
EP0966291A1 (fr) 1999-12-29
KR100504287B1 (ko) 2005-07-28
GR3035553T3 (en) 2001-06-29
ZA981958B (en) 1999-09-09
DK0966291T3 (da) 2002-02-25
ZA981953B (en) 1999-09-09
AP1162A (en) 2003-06-30
PT864329E (pt) 2001-03-30
PL335444A1 (en) 2000-04-25
AU6828698A (en) 1998-09-29
US6511453B2 (en) 2003-01-28
DE59709351D1 (de) 2003-03-27
EP0864328A1 (fr) 1998-09-16
CA2283227A1 (fr) 1998-09-17
SI0966291T1 (en) 2002-04-30
PL189841B1 (pl) 2005-09-30
SK118799A3 (en) 2000-05-16
CZ317399A3 (cs) 2000-01-12
PT966291E (pt) 2002-03-28
HUP0001510A3 (en) 2000-12-28
ID23151A (id) 2000-03-23
US20020052573A1 (en) 2002-05-02
EP0864329B1 (fr) 2000-12-13
ES2152608T3 (es) 2001-02-01
DE69802268D1 (de) 2001-12-06
HUP0001510A2 (hu) 2000-09-28
TR199902205T2 (xx) 1999-12-21
ATE232735T1 (de) 2003-03-15
BG64583B1 (bg) 2005-08-31
JPH10251142A (ja) 1998-09-22
DE19709704A1 (de) 1998-09-24
EE9900399A (et) 2000-04-17
EP0966291B1 (fr) 2001-10-31
BG103712A (en) 2000-04-28
KR20000076077A (ko) 2000-12-26
OA11156A (fr) 2003-04-22
CZ292767B6 (cs) 2003-12-17
CN1255065A (zh) 2000-05-31
DE69802268T2 (de) 2002-05-16
HK1028335A1 (en) 2001-02-16
IL131557A (en) 2004-06-20
RU2204397C2 (ru) 2003-05-20
TW396040B (en) 2000-07-01
EP0864328B1 (fr) 2003-02-19
NO994091D0 (no) 1999-08-24
ES2162437T3 (es) 2001-12-16
US6197323B1 (en) 2001-03-06
NZ337534A (en) 2001-02-23
DE59702760D1 (de) 2001-01-18
DK0864329T3 (da) 2001-04-09
WO1998040084A1 (fr) 1998-09-17
AU738946C (en) 2002-05-02
BR9808227A (pt) 2000-05-16
KR20000076117A (ko) 2000-12-26
NO994091L (no) 1999-10-27
CN1104901C (zh) 2003-04-09
AP9901630A0 (en) 1999-09-30
AU738946B2 (en) 2001-09-27
DE19709704C2 (de) 1999-11-04
SK284249B6 (sk) 2004-12-01
HU224985B1 (en) 2006-05-29
US6328708B1 (en) 2001-12-11
EE03807B1 (et) 2002-08-15

Similar Documents

Publication Publication Date Title
AU738946C (en) Medicinal preparation containing a lipophilic inert gas
EP0583358B1 (fr) Respiration liquide partielle des fluorocarbones
EP1558226B1 (fr) Methode de cardioprotection et de neuroprotection par administration intraveineuse d'anesthesiques volatiles halogenes
AU719407B2 (en) Device for controlled anaesthesia, analgesia and/or sedation
UA64744C2 (en) Medicinal preparation containing lipophilic inert gas
HK1028335B (en) Medicinal preparation containing a lipophilic inert gas

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 98804792.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 131557

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 68286/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 337534

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 118799

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 1998913672

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PV1999-3173

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1019997008165

Country of ref document: KR

Ref document number: 1999/02205

Country of ref document: TR

ENP Entry into the national phase

Ref document number: 2283227

Country of ref document: CA

Ref document number: 2283227

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/008308

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 1998913672

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1999-3173

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref document number: 1998539194

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 1019997008165

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1998913672

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 68286/98

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: PV1999-3173

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 1019997008165

Country of ref document: KR